View ValuationJohnson Matthey 将来の成長Future 基準チェック /36Johnson Mattheyの収益は年間34%で減少すると予測されていますが、年間利益は年間50.1%で増加すると予測されています。EPS は年間 増加すると予測されています。自己資本利益率は 3 年後に16.6% 53.8%なると予測されています。主要情報50.1%収益成長率53.77%EPS成長率Chemicals 収益成長38.9%収益成長率-34.0%将来の株主資本利益率16.57%アナリストカバレッジGood最終更新日21 May 2026今後の成長に関する最新情報お知らせ • May 25+ 1 more updateJohnson Matthey PLC Provides Earnings Guidance for the Year Ending 31 March 2025Johnson Matthey PLC provided earnings guidance for the year ending March 31, 2025. For the period, company expects at least mid single digit growth in underlying operating performance at constant precious metal prices and constant currency.すべての更新を表示Recent updatesBoard Change • May 21High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CFO & Executive Director Alastair Judge was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.お知らせ • Nov 22+ 4 more updatesJohnson Matthey plc Announces Departure of Anish Taneja, Chief Executive of Clean Air and Hydrogen TechnologiesJohnson Matthey Plc announced that Anish Taneja, Chief Executive of Clean Air and Hydrogen Technologies, has decided to leave Johnson Matthey to take up an external position, based in Germany. Anish joined JM in 2022 and has successfully strengthened Clean Air, leaving the business well positioned to deliver on its strategy.お知らせ • Nov 21Johnson Matthey Plc to Report Fiscal Year 2026 Results on May 28, 2026Johnson Matthey Plc announced that they will report fiscal year 2026 results on May 28, 2026お知らせ • Jul 18Johnson Matthey Plc Approves Final DividendJohnson Matthey Plc announced at annual general meeting held on July 17, 2025, the shareholders approved final dividend of 55.00 pence per share.お知らせ • Jul 17Johnson Matthey plc Announces Board ChangesJohnson Matthey announced the appointment of Andrew Cosslett as Non-Executive Chair of the Board, with effect from the conclusion of Annual General Meeting. Andrew will succeed Patrick Thomas who will step down from the Board at the end of the AGM. Andrew is an experienced Chair with a strong track record in leading significant transformational and cultural change and delivering long-term shareholder value. He has held a number of senior executive and non-executive roles across a range of sectors, including consumer goods, hospitality and media. His extensive boardroom experience and commercial insight will support the Company's strategy as it becomes a highly focused and leaner business, driving sustainable cash generation. Andrew is currently Chair of ITV plc and previously served as Chair of Kingfisher plc and the Rugby Football Union (RFU). He is the former Chief Executive Officer of both InterContinental Hotels Group PLC and Fitness First. Andrew received a CBE for services to the RFU in the 2022 New Year's Honours List. Upon joining the Board, Andrew will also become a member and Chair of the Nomination Committee and member of the Societal Value Committee. Andrew has been a director of ITV plc since June 2022. From June 2017 until June 2024, Andrew was a director of Kingfisher plc.お知らせ • May 22+ 5 more updatesJohnson Matthey Plc, Annual General Meeting, Jul 17, 2025Johnson Matthey Plc, Annual General Meeting, Jul 17, 2025.お知らせ • Feb 10+ 1 more updateJohnson Matthey plc Announces Board ChangesJohnson Matthey announced that Richard Pike will join the Company's Board on 1 April 2025. Richard joins the Company from DS Smith Plc where he has been Group Finance Director since March 2023. He brings strong financial leadership and a deep understanding of manufacturing and recycling industries. Richard also has significant experience of enhancing cash flow and improving cost efficiencies. Richard previously held the roles of Chief Financial Officer at Biffa plc and as Group Finance Director of AB Sugar and Managing Director of British Sugar (both parts of ABF plc), as well as Chief Financial Officer of Boparan Holdings Limited. Earlier in his career Richard trained and qualified as a chartered accountant with PwC, and thereafter went on to hold a variety of roles at Scapa Group plc, Pilkington plc and Manchester Airports Group. From June 2023 until February 2025, Richard Pike was a director of DS Smith plc. From September 2018 until March 2023, Richard Pike was a director of Biffa plc. Following nearly seven years as Chair of Johnson Matthey, Patrick Thomas has informed the Board that he does not intend to seek re-election at the Company's AGM on 17 July 2025 and so will step down from the Board and his position as Chair immediately following the AGM. Johnson Matthey's Nomination Committee has commenced a search for Patrick's successor as Chair and a further update will be provided in due course. The Board and Nomination Committee regularly reviews the effectiveness and make up of the Board and, as part of that, will continue to consider opportunities to augment the Board with new directors to reflect the group's transformation strategy.お知らせ • Jan 27Johnson Matthey plc Announces Establishment of Investment CommitteeJohnson Matthey Plc announced the establishment of an Investment Committee of the Board. The Committee, established on 24th January 2025, will reinforce the Company's investment strategies and capital allocation. The Board recognises the need for the Company to remain agile in uncertain markets and adapt its investment strategy and capital allocation as needed, alongside identifying initiatives to accelerate and deliver cash generation and enhanced returns on capital. The Committee will provide additional oversight to these areas in line with the Company's commitment to delivering sustainable shareholder value. Specific responsibilities of the Committee will include review and endorsement of i) investment and capital allocation strategy, ii) major capital projects and, iii) M&A activity. In discharging these duties, the Committee will give consideration to leading market indicators, execution risk, and levels of return and cash generation for shareholders. The Committee will be chaired by Barbara Jeremiah, Senior Independent Director and will initially consist of the following additional members: Liam Condon- Chief Executive, Sinead Lynch-Independent Non-Executive Director, Stephen Oxley-Chief Financial Officer, and Doug Webb-Independent Non-Executive Director.お知らせ • Nov 27+ 1 more updateJohnson Matthey plc Approves an Interim Dividend, Payable on 4 February 2025Johnson Matthey Plc board has approved an interim dividend of 22.0 pence per share, maintained at the same level as the prior year (First half 2023/24: 22.0 pence per share). The interim dividend will be paid on 4 February 2025, with an ex-dividend date of 5 December 2024, to shareholders on the register on 6 December 2024.お知らせ • Sep 23Johnson Matthey Plc(LSE:JMAT) dropped from FTSE All-World Index (USD)Johnson Matthey Plc(LSE:JMAT) dropped from FTSE All-World Index (USD)お知らせ • Sep 09Johnson Matthey plc Announces Board and Committee ChangesJohnson Matthey Plc announced the appointment of Sinead Lynch as an independent Non-Executive Director with effect from 1st January 2025. Sinead will also become a member of the Remuneration, Nomination and Societal Value Committees. Sinead brings a deep understanding of low carbon energy and sustainability, having spent 30 years in the energy sector at Royal Dutch Shell ("Shell") and BG Group ("BG"), including the last 10 years in an executive capacity. Most recently, she led Shell's Low Carbon Fuels business, developing technologies and investing in projects to produce sustainable renewable fuels at scale. Prior to this, Sinead was the UK Country Chair at Shell and led the Safety and Sustainability division of BG before its acquisition by Shell. She was also co-chair of the UK Hydrogen Advisory Council from 1st July 2020 until 1st August 2021. Following a seven-year tenure, Jane Griffiths has taken the decision to step down as Chair of the Societal Value Committee and from the Board on 31st December 2024. Rita Forst will succeed Jane as Chair of the Societal Value Committee from 1st January 2025.お知らせ • Jul 19Johnson Matthey Plc Declares a Final DividendJohnson Matthey Plc at its Annual General Meeting held on 18 July 2024 declared a final dividend of 55.00 pence per ordinary share.お知らせ • Jul 04Johnson Matthey Plc (LSE:JMAT) announces an Equity Buyback for £250 million worth of its shares.Johnson Matthey Plc (LSE:JMAT) announces a share repurchase program. Under the program, the company will repurchase up to £250 million worth of its shares. The sole purpose of the program is to reduce the share capital of the company. All shares repurchased will be cancelled. The program will commence immediately and end no later than November 4, 2024.お知らせ • Jul 02Montagu Private Equity LLP acquired Medical Device Components business from Johnson Matthey Plc (LSE:JMAT).Montagu Private Equity LLP agreed to acquire Medical Device Components business from Johnson Matthey Plc (LSE:JMAT) for £550 million on March 20, 2024. The consideration will be paid on a cash free debt free basis. The sale proceeds will be payable in cash at completion. The gross assets that are the subject of this transaction amounted to £60 million as at September 30, 2023. Transaction is subject to regulatory approval. The transaction is expected to complete around Q3 2024. Goldman Sachs International acted as exclusive financial adviser to Johnson Matthey. Raymond James & Associates, Inc. acted as financial advisor, Kirkland & Ellis LLP as legal advisor, and PwC acted as accounting due diligence transaction advisor to Montagu. Montagu Private Equity LLP completed the acquisition of Medical Device Components business from Johnson Matthey Plc (LSE:JMAT) on July 1, 2024.お知らせ • Jul 01Johnson Matthey plc Announces Stephen Oxley, Chief Financial Officer to Step DownJohnson Matthey Plc announced that Stephen Oxley, Chief Financial Officer, has advised the board that he has decided to leave the Company in 2025 to pursue another opportunity. Stephen will continue with his existing responsibilities and will step down from the board by no later than 31st March 2025. The board has commenced a process to identify a successor to Stephen and an appointment will be announced in due course.Declared Dividend • May 27Final dividend of UK£0.55 announcedDividend of UK£0.55 is the same as last year. Ex-date: 6th June 2024 Payment date: 6th August 2024 Dividend yield will be 4.3%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is not covered by earnings (131% earnings payout ratio). However, it is covered by cash flows (63% cash payout ratio). The dividend has increased by an average of 2.5% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 45% to bring the payout ratio under control. EPS is expected to grow by 156% over the next 3 years, which is sufficient to bring the dividend into a sustainable range.お知らせ • May 25+ 1 more updateJohnson Matthey PLC Provides Earnings Guidance for the Year Ending 31 March 2025Johnson Matthey PLC provided earnings guidance for the year ending March 31, 2025. For the period, company expects at least mid single digit growth in underlying operating performance at constant precious metal prices and constant currency.Reported Earnings • May 25Full year 2024 earnings released: EPS: UK£0.59 (vs UK£1.44 in FY 2023)Full year 2024 results: EPS: UK£0.59 (down from UK£1.44 in FY 2023). Revenue: UK£12.8b (down 14% from FY 2023). Net income: UK£108.0m (down 59% from FY 2023). Profit margin: 0.8% (down from 1.8% in FY 2023). Revenue is expected to fall by 60% p.a. on average during the next 3 years compared to a 8.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.お知らせ • May 24Johnson Matthey Plc to Report First Half, 2025 Results on Nov 27, 2024Johnson Matthey Plc announced that they will report first half, 2025 results on Nov 27, 2024Reported Earnings • Nov 25First half 2024 earnings released: EPS: UK£0.34 (vs UK£0.82 in 1H 2023)First half 2024 results: EPS: UK£0.34 (down from UK£0.82 in 1H 2023). Revenue: UK£6.53b (down 11% from 1H 2023). Net income: UK£63.0m (down 58% from 1H 2023). Profit margin: 1.0% (down from 2.0% in 1H 2023). Revenue is expected to fall by 35% p.a. on average during the next 3 years compared to a 4.7% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.New Risk • Nov 24New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 42% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (42% net debt to equity). Dividend is not well covered by cash flows (313% cash payout ratio). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.3% net profit margin).お知らせ • Nov 22+ 4 more updatesJohnson Matthey Plc to Report Fiscal Year 2024 Results on May 23, 2024Johnson Matthey Plc announced that they will report fiscal year 2024 results on May 23, 2024New Risk • Oct 06New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (5.6% increase in shares outstanding).お知らせ • Sep 18Johnson Matthey Plc(LSE:JMAT) dropped from FTSE 100 IndexJohnson Matthey Plc(LSE:JMAT) dropped from FTSE 100 Indexお知らせ • Jul 23Johnson Matthey plc Approves Final DividendJohnson Matthey Plc approved to declare a final dividend of 55.00 pence per ordinary share.お知らせ • Jun 13Johnson Matthey Plc to Report First Half, 2024 Results on Nov 23, 2023Johnson Matthey Plc announced that they will report first half, 2024 results on Nov 23, 2023Upcoming Dividend • Jun 02Upcoming dividend of UK£0.55 per share at 4.4% yieldEligible shareholders must have bought the stock before 08 June 2023. Payment date: 01 August 2023. Payout ratio is a comfortable 53% but the company is not cash flow positive. Trailing yield: 4.4%. Lower than top quartile of British dividend payers (5.9%). Higher than average of industry peers (2.6%).Reported Earnings • May 26Full year 2023 earnings released: EPS: UK£1.44 (vs UK£0.61 in FY 2022)Full year 2023 results: EPS: UK£1.44 (up from UK£0.61 in FY 2022). Revenue: UK£14.9b (down 6.8% from FY 2022). Net income: UK£264.0m (up 128% from FY 2022). Profit margin: 1.8% (up from 0.7% in FY 2022). The increase in margin was driven by lower expenses. Revenue is expected to decline by 48% p.a. on average during the next 3 years, while revenues in the Chemicals industry in the United Kingdom are expected to grow by 2.2%. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.お知らせ • May 25+ 1 more updateJohnson Matthey plc Proposes Final Ordinary Dividend, Payable on August 1, 2023Johnson Matthey Plc announced that the board will propose a final ordinary dividend for the year of 55.0 pence per share at the Annual General Meeting (AGM) on 20th July 2023. Subject to approval by shareholders, the final dividend will be paid on August 1, 2023, with an ex-dividend date of June 8, 2023.お知らせ • May 05Souter Investments Limited and Sullivan Street Partners Ltd agreed to acquire Diagnostic Services Business of Johnson Matthey Plc for £55 million.Souter Investments Limited and Sullivan Street Partners Ltd agreed to acquire Diagnostic Services Business of Johnson Matthey Plc for £55 million on May 3, 2023. The transaction is subject to customary completion conditions. The transaction is expected to complete in the third quarter of calendar 2023. Paul Mudie of Slaughter and May acted as legal advisor to Johnson Matthey Plc.お知らせ • Jan 05+ 1 more updateJohnson Matthey Plc(LSE:JMAT) dropped from FTSE 250 IndexJohnson Matthey Plc(LSE:JMAT) dropped from FTSE 250 IndexUpcoming Dividend • Dec 01Upcoming dividend of UK£0.22 per shareEligible shareholders must have bought the stock before 08 December 2022. Payment date: 01 February 2023. Payout ratio is a comfortable 36% but the company is not cash flow positive. Trailing yield: 3.7%. Lower than top quartile of British dividend payers (5.7%). Higher than average of industry peers (2.9%).Reported Earnings • Nov 24First half 2023 earnings released: EPS: UK£0.82 (vs UK£0.14 loss in 1H 2022)First half 2023 results: EPS: UK£0.82 (up from UK£0.14 loss in 1H 2022). Revenue: UK£7.33b (down 15% from 1H 2022). Net income: UK£150.0m (up UK£178.0m from 1H 2022). Profit margin: 2.0% (up from net loss in 1H 2022). The move to profitability was driven by lower expenses. Revenue is expected to fall by 14% p.a. on average during the next 3 years compared to a 9.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.お知らせ • Nov 23+ 1 more updateJohnson Matthey Plc to Report Fiscal Year 2023 Results on May 26, 2023Johnson Matthey Plc announced that they will report fiscal year 2023 results on May 26, 2023Upcoming Dividend • Jun 02Upcoming dividend of UK£0.55 per shareEligible shareholders must have bought the stock before 09 June 2022. Payment date: 02 August 2022. The company is paying out more than 100% of its profits and is paying out 91% of its cash flow. Trailing yield: 3.7%. Lower than top quartile of British dividend payers (4.9%). Higher than average of industry peers (2.8%).Reported Earnings • May 27Full year 2022 earnings released: EPS: UK£0.60 (vs UK£1.06 in FY 2021)Full year 2022 results: EPS: UK£0.60 (down from UK£1.06 in FY 2021). Revenue: UK£16.0b (up 2.2% from FY 2021). Net income: UK£116.0m (down 43% from FY 2021). Profit margin: 0.7% (down from 1.3% in FY 2021). Over the next year, revenue is expected to shrink by 75% compared to a 18% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • May 03Investor sentiment improved over the past weekAfter last week's 23% share price gain to UK£22.44, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 21x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at UK£29.26 per share.Buying Opportunity • Feb 25Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 17%. The fair value is estimated to be UK£22.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% per annum over the last 3 years. Earnings per share has declined by 36% per annum over the last 3 years.Buying Opportunity • Feb 25Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 17%. The fair value is estimated to be UK£22.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% per annum over the last 3 years. Earnings per share has declined by 36% per annum over the last 3 years.Buying Opportunity • Feb 09Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 22%. The fair value is estimated to be UK£22.17, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% per annum over the last 3 years. Earnings per share has declined by 36% per annum over the last 3 years.Recent Insider Transactions • Jan 07Independent Non-Executive Director recently bought UK£52k worth of stockOn the 4th of January, Doug Webb bought around 3k shares on-market at roughly UK£20.73 per share. In the last 3 months, there was an even bigger purchase from another insider worth UK£97k. Insiders have collectively bought UK£240k more in shares than they have sold in the last 12 months.Recent Insider Transactions • Dec 25CEO & Executive Director recently bought UK£97k worth of stockOn the 22nd of December, Robert MacLeod bought around 5k shares on-market at roughly UK£19.46 per share. This was the largest purchase by an insider in the last 3 months. This was Robert's only on-market trade for the last 12 months.Reported Earnings • Nov 27First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: UK£0.14 loss per share (down from UK£0.13 profit in 1H 2021). Revenue: UK£8.59b (up 23% from 1H 2021). Net loss: UK£28.0m (down 217% from profit in 1H 2021). Revenue missed analyst estimates by 4.3%. Over the next year, revenue is expected to shrink by 75% compared to a 1.3% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.Valuation Update With 7 Day Price Move • Nov 12Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to UK£22.52, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 24x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 19% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at UK£36.18 per share.Board Change • Nov 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Rita Forst was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • Jun 17Full year 2021 earnings released: EPS UK£1.06 (vs UK£1.33 in FY 2020)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: UK£15.7b (up 7.5% from FY 2020). Net income: UK£205.0m (down 20% from FY 2020). Profit margin: 1.3% (down from 1.7% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.Upcoming Dividend • Jun 03Upcoming dividend of UK£0.50 per shareEligible shareholders must have bought the stock before 10 June 2021. Payment date: 03 August 2021. Trailing yield: 2.3%. Lower than top quartile of British dividend payers (4.0%). Higher than average of industry peers (1.6%).Reported Earnings • May 28Full year 2021 earnings released: EPS UK£1.06 (vs UK£1.33 in FY 2020)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: UK£15.7b (up 7.5% from FY 2020). Net income: UK£205.0m (down 20% from FY 2020). Profit margin: 1.3% (down from 1.7% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.Is New 90 Day High Low • Feb 16New 90-day high: UK£30.83The company is up 21% from its price of UK£25.43 on 18 November 2020. The British market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£30.27 per share.Executive Departure • Feb 06Independent Non-Executive Director has left the companyOn the 26th of January, Christopher Mottershead's tenure as Independent Non-Executive Director ended after 6.0 years in the role. As of September 2020, Christopher personally held 2.81k shares (UK£66k worth at the time). A total of 6 executives have left over the last 12 months.Is New 90 Day High Low • Jan 27New 90-day high: UK£30.00The company is up 37% from its price of UK£21.97 on 28 October 2020. The British market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£24.56 per share.Is New 90 Day High Low • Jan 06New 90-day high: UK£27.03The company is up 11% from its price of UK£24.39 on 08 October 2020. The British market is also up 11% over the last 90 days, indicating the company’s price trend is similar to the market over that time. Its price trend is also similar to the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£25.96 per share.業績と収益の成長予測BATS-CHIXE:JMATL - アナリストの将来予測と過去の財務データ ( )GBP Millions日付収益収益フリー・キャッシュフロー営業活動によるキャッシュ平均アナリスト数3/31/20292,61826529351323/31/20282,59324731448843/31/20272,63738433148353/31/20262,97816814631059/30/202511,718-91197564N/A6/30/202511,696141103473N/A3/31/202511,6743738381N/A12/31/202411,48641517358N/A9/30/202411,621493-11334N/A6/30/202412,232301107463N/A3/31/202412,843108224592N/A12/31/202313,490143135487N/A9/30/202314,13617745382N/A6/30/202314,53522110337N/A3/31/202314,933264-25291N/A12/31/202214,892277-46315N/A9/30/202214,850290-68338N/A6/30/202215,43820342472N/A3/31/202216,025116152605N/A9/30/202116,959146309699N/A6/30/202116,197170349734N/A3/31/202115,435194388769N/A12/31/202015,2061545971,004N/A9/30/202014,7381038051,239N/A6/30/202014,658179480919N/A3/31/202014,577255155598N/A12/31/201913,58732015431N/A9/30/201912,596385-126263N/A6/30/201911,671399N/A299N/A3/31/201910,745413N/A334N/A12/31/20189,754373N/A312N/A9/30/20188,763333N/A290N/A6/30/20189,519316N/A338N/A3/31/201810,274298N/A386N/A12/31/201711,579338N/A397N/A9/30/201712,884377N/A407N/A6/30/201712,458382N/A465N/A3/31/201712,031386N/A523N/A12/31/201611,307308N/A484N/A9/30/201610,584231N/A445N/A6/30/201610,649282N/A656N/A3/31/201610,714333N/A867N/A12/31/201510,864434N/A687N/A9/30/201511,015535N/A508N/A6/30/201510,537482N/A317N/Aもっと見るアナリストによる今後の成長予測収入対貯蓄率: JMATLは今後 3 年間で収益性が向上すると予測されており、これは 貯蓄率 ( 3.4% ) よりも高い成長率であると考えられます。収益対市場: JMATL今後 3 年間で収益性が向上すると予想されており、これは市場平均を上回る成長と考えられます。高成長収益: JMATL今後 3 年以内に収益を上げることが予想されます。収益対市場: JMATLの収益は今後 3 年間で減少すると予想されています (年間-34% )。高い収益成長: JMATLの収益は今後 3 年間で減少すると予測されています (年間-34% )。一株当たり利益成長率予想将来の株主資本利益率将来のROE: JMATLの 自己資本利益率 は、3年後には低くなると予測されています ( 16.6 %)。成長企業の発掘7D1Y7D1Y7D1YMaterials 業界の高成長企業。View Past Performance企業分析と財務データの現状データ最終更新日（UTC時間）企業分析2026/05/22 09:57終値2026/05/22 00:00収益2025/09/30年間収益2025/03/31データソース企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。パッケージデータタイムフレーム米国ソース例会社財務10年損益計算書キャッシュ・フロー計算書貸借対照表SECフォーム10-KSECフォーム10-Qアナリストのコンセンサス予想+プラス3年予想財務アナリストの目標株価アナリストリサーチレポートBlue Matrix市場価格30年株価配当、分割、措置ICEマーケットデータSECフォームS-1所有権10年トップ株主インサイダー取引SECフォーム4SECフォーム13Dマネジメント10年リーダーシップ・チーム取締役会SECフォーム10-KSECフォームDEF 14A主な進展10年会社からのお知らせSECフォーム8-K* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。分析モデルとスノーフレーク本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。業界およびセクターの指標私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。アナリスト筋Johnson Matthey Plc 6 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。34 アナリスト機関Sebastian BrayBerenbergGunther ZechmannBernsteinLaurent FavreBNP Paribas31 その他のアナリストを表示
お知らせ • May 25+ 1 more updateJohnson Matthey PLC Provides Earnings Guidance for the Year Ending 31 March 2025Johnson Matthey PLC provided earnings guidance for the year ending March 31, 2025. For the period, company expects at least mid single digit growth in underlying operating performance at constant precious metal prices and constant currency.
Board Change • May 21High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. CFO & Executive Director Alastair Judge was the last director to join the board, commencing their role in 2026. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
お知らせ • Nov 22+ 4 more updatesJohnson Matthey plc Announces Departure of Anish Taneja, Chief Executive of Clean Air and Hydrogen TechnologiesJohnson Matthey Plc announced that Anish Taneja, Chief Executive of Clean Air and Hydrogen Technologies, has decided to leave Johnson Matthey to take up an external position, based in Germany. Anish joined JM in 2022 and has successfully strengthened Clean Air, leaving the business well positioned to deliver on its strategy.
お知らせ • Nov 21Johnson Matthey Plc to Report Fiscal Year 2026 Results on May 28, 2026Johnson Matthey Plc announced that they will report fiscal year 2026 results on May 28, 2026
お知らせ • Jul 18Johnson Matthey Plc Approves Final DividendJohnson Matthey Plc announced at annual general meeting held on July 17, 2025, the shareholders approved final dividend of 55.00 pence per share.
お知らせ • Jul 17Johnson Matthey plc Announces Board ChangesJohnson Matthey announced the appointment of Andrew Cosslett as Non-Executive Chair of the Board, with effect from the conclusion of Annual General Meeting. Andrew will succeed Patrick Thomas who will step down from the Board at the end of the AGM. Andrew is an experienced Chair with a strong track record in leading significant transformational and cultural change and delivering long-term shareholder value. He has held a number of senior executive and non-executive roles across a range of sectors, including consumer goods, hospitality and media. His extensive boardroom experience and commercial insight will support the Company's strategy as it becomes a highly focused and leaner business, driving sustainable cash generation. Andrew is currently Chair of ITV plc and previously served as Chair of Kingfisher plc and the Rugby Football Union (RFU). He is the former Chief Executive Officer of both InterContinental Hotels Group PLC and Fitness First. Andrew received a CBE for services to the RFU in the 2022 New Year's Honours List. Upon joining the Board, Andrew will also become a member and Chair of the Nomination Committee and member of the Societal Value Committee. Andrew has been a director of ITV plc since June 2022. From June 2017 until June 2024, Andrew was a director of Kingfisher plc.
お知らせ • May 22+ 5 more updatesJohnson Matthey Plc, Annual General Meeting, Jul 17, 2025Johnson Matthey Plc, Annual General Meeting, Jul 17, 2025.
お知らせ • Feb 10+ 1 more updateJohnson Matthey plc Announces Board ChangesJohnson Matthey announced that Richard Pike will join the Company's Board on 1 April 2025. Richard joins the Company from DS Smith Plc where he has been Group Finance Director since March 2023. He brings strong financial leadership and a deep understanding of manufacturing and recycling industries. Richard also has significant experience of enhancing cash flow and improving cost efficiencies. Richard previously held the roles of Chief Financial Officer at Biffa plc and as Group Finance Director of AB Sugar and Managing Director of British Sugar (both parts of ABF plc), as well as Chief Financial Officer of Boparan Holdings Limited. Earlier in his career Richard trained and qualified as a chartered accountant with PwC, and thereafter went on to hold a variety of roles at Scapa Group plc, Pilkington plc and Manchester Airports Group. From June 2023 until February 2025, Richard Pike was a director of DS Smith plc. From September 2018 until March 2023, Richard Pike was a director of Biffa plc. Following nearly seven years as Chair of Johnson Matthey, Patrick Thomas has informed the Board that he does not intend to seek re-election at the Company's AGM on 17 July 2025 and so will step down from the Board and his position as Chair immediately following the AGM. Johnson Matthey's Nomination Committee has commenced a search for Patrick's successor as Chair and a further update will be provided in due course. The Board and Nomination Committee regularly reviews the effectiveness and make up of the Board and, as part of that, will continue to consider opportunities to augment the Board with new directors to reflect the group's transformation strategy.
お知らせ • Jan 27Johnson Matthey plc Announces Establishment of Investment CommitteeJohnson Matthey Plc announced the establishment of an Investment Committee of the Board. The Committee, established on 24th January 2025, will reinforce the Company's investment strategies and capital allocation. The Board recognises the need for the Company to remain agile in uncertain markets and adapt its investment strategy and capital allocation as needed, alongside identifying initiatives to accelerate and deliver cash generation and enhanced returns on capital. The Committee will provide additional oversight to these areas in line with the Company's commitment to delivering sustainable shareholder value. Specific responsibilities of the Committee will include review and endorsement of i) investment and capital allocation strategy, ii) major capital projects and, iii) M&A activity. In discharging these duties, the Committee will give consideration to leading market indicators, execution risk, and levels of return and cash generation for shareholders. The Committee will be chaired by Barbara Jeremiah, Senior Independent Director and will initially consist of the following additional members: Liam Condon- Chief Executive, Sinead Lynch-Independent Non-Executive Director, Stephen Oxley-Chief Financial Officer, and Doug Webb-Independent Non-Executive Director.
お知らせ • Nov 27+ 1 more updateJohnson Matthey plc Approves an Interim Dividend, Payable on 4 February 2025Johnson Matthey Plc board has approved an interim dividend of 22.0 pence per share, maintained at the same level as the prior year (First half 2023/24: 22.0 pence per share). The interim dividend will be paid on 4 February 2025, with an ex-dividend date of 5 December 2024, to shareholders on the register on 6 December 2024.
お知らせ • Sep 23Johnson Matthey Plc(LSE:JMAT) dropped from FTSE All-World Index (USD)Johnson Matthey Plc(LSE:JMAT) dropped from FTSE All-World Index (USD)
お知らせ • Sep 09Johnson Matthey plc Announces Board and Committee ChangesJohnson Matthey Plc announced the appointment of Sinead Lynch as an independent Non-Executive Director with effect from 1st January 2025. Sinead will also become a member of the Remuneration, Nomination and Societal Value Committees. Sinead brings a deep understanding of low carbon energy and sustainability, having spent 30 years in the energy sector at Royal Dutch Shell ("Shell") and BG Group ("BG"), including the last 10 years in an executive capacity. Most recently, she led Shell's Low Carbon Fuels business, developing technologies and investing in projects to produce sustainable renewable fuels at scale. Prior to this, Sinead was the UK Country Chair at Shell and led the Safety and Sustainability division of BG before its acquisition by Shell. She was also co-chair of the UK Hydrogen Advisory Council from 1st July 2020 until 1st August 2021. Following a seven-year tenure, Jane Griffiths has taken the decision to step down as Chair of the Societal Value Committee and from the Board on 31st December 2024. Rita Forst will succeed Jane as Chair of the Societal Value Committee from 1st January 2025.
お知らせ • Jul 19Johnson Matthey Plc Declares a Final DividendJohnson Matthey Plc at its Annual General Meeting held on 18 July 2024 declared a final dividend of 55.00 pence per ordinary share.
お知らせ • Jul 04Johnson Matthey Plc (LSE:JMAT) announces an Equity Buyback for £250 million worth of its shares.Johnson Matthey Plc (LSE:JMAT) announces a share repurchase program. Under the program, the company will repurchase up to £250 million worth of its shares. The sole purpose of the program is to reduce the share capital of the company. All shares repurchased will be cancelled. The program will commence immediately and end no later than November 4, 2024.
お知らせ • Jul 02Montagu Private Equity LLP acquired Medical Device Components business from Johnson Matthey Plc (LSE:JMAT).Montagu Private Equity LLP agreed to acquire Medical Device Components business from Johnson Matthey Plc (LSE:JMAT) for £550 million on March 20, 2024. The consideration will be paid on a cash free debt free basis. The sale proceeds will be payable in cash at completion. The gross assets that are the subject of this transaction amounted to £60 million as at September 30, 2023. Transaction is subject to regulatory approval. The transaction is expected to complete around Q3 2024. Goldman Sachs International acted as exclusive financial adviser to Johnson Matthey. Raymond James & Associates, Inc. acted as financial advisor, Kirkland & Ellis LLP as legal advisor, and PwC acted as accounting due diligence transaction advisor to Montagu. Montagu Private Equity LLP completed the acquisition of Medical Device Components business from Johnson Matthey Plc (LSE:JMAT) on July 1, 2024.
お知らせ • Jul 01Johnson Matthey plc Announces Stephen Oxley, Chief Financial Officer to Step DownJohnson Matthey Plc announced that Stephen Oxley, Chief Financial Officer, has advised the board that he has decided to leave the Company in 2025 to pursue another opportunity. Stephen will continue with his existing responsibilities and will step down from the board by no later than 31st March 2025. The board has commenced a process to identify a successor to Stephen and an appointment will be announced in due course.
Declared Dividend • May 27Final dividend of UK£0.55 announcedDividend of UK£0.55 is the same as last year. Ex-date: 6th June 2024 Payment date: 6th August 2024 Dividend yield will be 4.3%, which is higher than the industry average of 3.0%. Sustainability & Growth Dividend is not covered by earnings (131% earnings payout ratio). However, it is covered by cash flows (63% cash payout ratio). The dividend has increased by an average of 2.5% per year over the past 10 years. However, payments have been volatile during that time. The company's earnings per share (EPS) would need to grow by 45% to bring the payout ratio under control. EPS is expected to grow by 156% over the next 3 years, which is sufficient to bring the dividend into a sustainable range.
お知らせ • May 25+ 1 more updateJohnson Matthey PLC Provides Earnings Guidance for the Year Ending 31 March 2025Johnson Matthey PLC provided earnings guidance for the year ending March 31, 2025. For the period, company expects at least mid single digit growth in underlying operating performance at constant precious metal prices and constant currency.
Reported Earnings • May 25Full year 2024 earnings released: EPS: UK£0.59 (vs UK£1.44 in FY 2023)Full year 2024 results: EPS: UK£0.59 (down from UK£1.44 in FY 2023). Revenue: UK£12.8b (down 14% from FY 2023). Net income: UK£108.0m (down 59% from FY 2023). Profit margin: 0.8% (down from 1.8% in FY 2023). Revenue is expected to fall by 60% p.a. on average during the next 3 years compared to a 8.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 1% per year but the company’s share price has fallen by 16% per year, which means it is significantly lagging earnings.
お知らせ • May 24Johnson Matthey Plc to Report First Half, 2025 Results on Nov 27, 2024Johnson Matthey Plc announced that they will report first half, 2025 results on Nov 27, 2024
Reported Earnings • Nov 25First half 2024 earnings released: EPS: UK£0.34 (vs UK£0.82 in 1H 2023)First half 2024 results: EPS: UK£0.34 (down from UK£0.82 in 1H 2023). Revenue: UK£6.53b (down 11% from 1H 2023). Net income: UK£63.0m (down 58% from 1H 2023). Profit margin: 1.0% (down from 2.0% in 1H 2023). Revenue is expected to fall by 35% p.a. on average during the next 3 years compared to a 4.7% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has increased by 21% per year but the company’s share price has fallen by 12% per year, which means it is significantly lagging earnings.
New Risk • Nov 24New minor risk - Financial positionThe company has a high level of debt. Net debt to equity ratio: 42% This is considered a minor risk. Having a high level of debt increases the company's balance sheet risk. The company has a higher interest repayment burden, leading to the need to allocate a greater amount of its earnings towards servicing the debt, potentially limiting growth options or shareholder distributions. It can also increase the risk of bankruptcy if business conditions deteriorate enough that the company can no longer meet its debt obligations. Currently, the following risks have been identified for the company: Minor Risks High level of debt (42% net debt to equity). Dividend is not well covered by cash flows (313% cash payout ratio). Large one-off items impacting financial results. Profit margins are more than 30% lower than last year (1.3% net profit margin).
お知らせ • Nov 22+ 4 more updatesJohnson Matthey Plc to Report Fiscal Year 2024 Results on May 23, 2024Johnson Matthey Plc announced that they will report fiscal year 2024 results on May 23, 2024
New Risk • Oct 06New minor risk - Shareholder dilutionThe company's shareholders have been diluted in the past year. Increase in shares outstanding: 5.6% This is considered a minor risk. Shareholder dilution occurs when there is an increase in the number of shares on issue that is not proportionally distributed between all shareholders. Often due to the company raising equity capital or some options being converted into stock. All else being equal, if there are more shares outstanding then each existing share will be entitled to a lower proportion of the company's total earnings, thus reducing earnings per share (EPS). While dilution might not always result in lower EPS (like if the company is using the capital to fund an EPS accretive acquisition) in a lot cases it does, along with lower dividends per share and less voting power at shareholder meetings. Currently, the following risks have been identified for the company: Minor Risks Paying a dividend despite having no free cash flows. Shareholders have been diluted in the past year (5.6% increase in shares outstanding).
お知らせ • Sep 18Johnson Matthey Plc(LSE:JMAT) dropped from FTSE 100 IndexJohnson Matthey Plc(LSE:JMAT) dropped from FTSE 100 Index
お知らせ • Jul 23Johnson Matthey plc Approves Final DividendJohnson Matthey Plc approved to declare a final dividend of 55.00 pence per ordinary share.
お知らせ • Jun 13Johnson Matthey Plc to Report First Half, 2024 Results on Nov 23, 2023Johnson Matthey Plc announced that they will report first half, 2024 results on Nov 23, 2023
Upcoming Dividend • Jun 02Upcoming dividend of UK£0.55 per share at 4.4% yieldEligible shareholders must have bought the stock before 08 June 2023. Payment date: 01 August 2023. Payout ratio is a comfortable 53% but the company is not cash flow positive. Trailing yield: 4.4%. Lower than top quartile of British dividend payers (5.9%). Higher than average of industry peers (2.6%).
Reported Earnings • May 26Full year 2023 earnings released: EPS: UK£1.44 (vs UK£0.61 in FY 2022)Full year 2023 results: EPS: UK£1.44 (up from UK£0.61 in FY 2022). Revenue: UK£14.9b (down 6.8% from FY 2022). Net income: UK£264.0m (up 128% from FY 2022). Profit margin: 1.8% (up from 0.7% in FY 2022). The increase in margin was driven by lower expenses. Revenue is expected to decline by 48% p.a. on average during the next 3 years, while revenues in the Chemicals industry in the United Kingdom are expected to grow by 2.2%. Over the last 3 years on average, earnings per share has increased by 14% per year but the company’s share price has fallen by 5% per year, which means it is significantly lagging earnings.
お知らせ • May 25+ 1 more updateJohnson Matthey plc Proposes Final Ordinary Dividend, Payable on August 1, 2023Johnson Matthey Plc announced that the board will propose a final ordinary dividend for the year of 55.0 pence per share at the Annual General Meeting (AGM) on 20th July 2023. Subject to approval by shareholders, the final dividend will be paid on August 1, 2023, with an ex-dividend date of June 8, 2023.
お知らせ • May 05Souter Investments Limited and Sullivan Street Partners Ltd agreed to acquire Diagnostic Services Business of Johnson Matthey Plc for £55 million.Souter Investments Limited and Sullivan Street Partners Ltd agreed to acquire Diagnostic Services Business of Johnson Matthey Plc for £55 million on May 3, 2023. The transaction is subject to customary completion conditions. The transaction is expected to complete in the third quarter of calendar 2023. Paul Mudie of Slaughter and May acted as legal advisor to Johnson Matthey Plc.
お知らせ • Jan 05+ 1 more updateJohnson Matthey Plc(LSE:JMAT) dropped from FTSE 250 IndexJohnson Matthey Plc(LSE:JMAT) dropped from FTSE 250 Index
Upcoming Dividend • Dec 01Upcoming dividend of UK£0.22 per shareEligible shareholders must have bought the stock before 08 December 2022. Payment date: 01 February 2023. Payout ratio is a comfortable 36% but the company is not cash flow positive. Trailing yield: 3.7%. Lower than top quartile of British dividend payers (5.7%). Higher than average of industry peers (2.9%).
Reported Earnings • Nov 24First half 2023 earnings released: EPS: UK£0.82 (vs UK£0.14 loss in 1H 2022)First half 2023 results: EPS: UK£0.82 (up from UK£0.14 loss in 1H 2022). Revenue: UK£7.33b (down 15% from 1H 2022). Net income: UK£150.0m (up UK£178.0m from 1H 2022). Profit margin: 2.0% (up from net loss in 1H 2022). The move to profitability was driven by lower expenses. Revenue is expected to fall by 14% p.a. on average during the next 3 years compared to a 9.2% decline forecast for the Chemicals industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 16% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
お知らせ • Nov 23+ 1 more updateJohnson Matthey Plc to Report Fiscal Year 2023 Results on May 26, 2023Johnson Matthey Plc announced that they will report fiscal year 2023 results on May 26, 2023
Upcoming Dividend • Jun 02Upcoming dividend of UK£0.55 per shareEligible shareholders must have bought the stock before 09 June 2022. Payment date: 02 August 2022. The company is paying out more than 100% of its profits and is paying out 91% of its cash flow. Trailing yield: 3.7%. Lower than top quartile of British dividend payers (4.9%). Higher than average of industry peers (2.8%).
Reported Earnings • May 27Full year 2022 earnings released: EPS: UK£0.60 (vs UK£1.06 in FY 2021)Full year 2022 results: EPS: UK£0.60 (down from UK£1.06 in FY 2021). Revenue: UK£16.0b (up 2.2% from FY 2021). Net income: UK£116.0m (down 43% from FY 2021). Profit margin: 0.7% (down from 1.3% in FY 2021). Over the next year, revenue is expected to shrink by 75% compared to a 18% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 44% per year but the company’s share price has only fallen by 9% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • May 03Investor sentiment improved over the past weekAfter last week's 23% share price gain to UK£22.44, the stock trades at a forward P/E ratio of 14x. Average forward P/E is 21x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 25% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at UK£29.26 per share.
Buying Opportunity • Feb 25Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 17%. The fair value is estimated to be UK£22.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% per annum over the last 3 years. Earnings per share has declined by 36% per annum over the last 3 years.
Buying Opportunity • Feb 25Now 22% undervalued after recent price dropOver the last 90 days, the stock is down 17%. The fair value is estimated to be UK£22.28, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% per annum over the last 3 years. Earnings per share has declined by 36% per annum over the last 3 years.
Buying Opportunity • Feb 09Now 21% undervalued after recent price dropOver the last 90 days, the stock is down 22%. The fair value is estimated to be UK£22.17, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has grown by 20% per annum over the last 3 years. Earnings per share has declined by 36% per annum over the last 3 years.
Recent Insider Transactions • Jan 07Independent Non-Executive Director recently bought UK£52k worth of stockOn the 4th of January, Doug Webb bought around 3k shares on-market at roughly UK£20.73 per share. In the last 3 months, there was an even bigger purchase from another insider worth UK£97k. Insiders have collectively bought UK£240k more in shares than they have sold in the last 12 months.
Recent Insider Transactions • Dec 25CEO & Executive Director recently bought UK£97k worth of stockOn the 22nd of December, Robert MacLeod bought around 5k shares on-market at roughly UK£19.46 per share. This was the largest purchase by an insider in the last 3 months. This was Robert's only on-market trade for the last 12 months.
Reported Earnings • Nov 27First half 2022 earnings: EPS in line with expectations, revenues disappointFirst half 2022 results: UK£0.14 loss per share (down from UK£0.13 profit in 1H 2021). Revenue: UK£8.59b (up 23% from 1H 2021). Net loss: UK£28.0m (down 217% from profit in 1H 2021). Revenue missed analyst estimates by 4.3%. Over the next year, revenue is expected to shrink by 75% compared to a 1.3% decline forecast for the industry in the United Kingdom. Over the last 3 years on average, earnings per share has fallen by 36% per year but the company’s share price has only fallen by 10% per year, which means it has not declined as severely as earnings.
Valuation Update With 7 Day Price Move • Nov 12Investor sentiment deteriorated over the past weekAfter last week's 18% share price decline to UK£22.52, the stock trades at a forward P/E ratio of 11x. Average forward P/E is 24x in the Chemicals industry in the United Kingdom. Total loss to shareholders of 19% over the past three years. Simply Wall St's valuation model estimates the intrinsic value at UK£36.18 per share.
Board Change • Nov 02High number of new directorsThere are 5 new directors who have joined the board in the last 3 years. Independent Non-Executive Director Rita Forst was the last director to join the board, commencing their role in 2021. The company’s lack of board continuity is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • Jun 17Full year 2021 earnings released: EPS UK£1.06 (vs UK£1.33 in FY 2020)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: UK£15.7b (up 7.5% from FY 2020). Net income: UK£205.0m (down 20% from FY 2020). Profit margin: 1.3% (down from 1.7% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 5% per year, which means it has not declined as severely as earnings.
Upcoming Dividend • Jun 03Upcoming dividend of UK£0.50 per shareEligible shareholders must have bought the stock before 10 June 2021. Payment date: 03 August 2021. Trailing yield: 2.3%. Lower than top quartile of British dividend payers (4.0%). Higher than average of industry peers (1.6%).
Reported Earnings • May 28Full year 2021 earnings released: EPS UK£1.06 (vs UK£1.33 in FY 2020)The company reported a soft full year result with weaker earnings and profit margins, although revenues improved. Full year 2021 results: Revenue: UK£15.7b (up 7.5% from FY 2020). Net income: UK£205.0m (down 20% from FY 2020). Profit margin: 1.3% (down from 1.7% in FY 2020). Over the last 3 years on average, earnings per share has fallen by 25% per year but the company’s share price has only fallen by 6% per year, which means it has not declined as severely as earnings.
Is New 90 Day High Low • Feb 16New 90-day high: UK£30.83The company is up 21% from its price of UK£25.43 on 18 November 2020. The British market is up 5.0% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 12% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£30.27 per share.
Executive Departure • Feb 06Independent Non-Executive Director has left the companyOn the 26th of January, Christopher Mottershead's tenure as Independent Non-Executive Director ended after 6.0 years in the role. As of September 2020, Christopher personally held 2.81k shares (UK£66k worth at the time). A total of 6 executives have left over the last 12 months.
Is New 90 Day High Low • Jan 27New 90-day high: UK£30.00The company is up 37% from its price of UK£21.97 on 28 October 2020. The British market is up 18% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Chemicals industry, which is up 17% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£24.56 per share.
Is New 90 Day High Low • Jan 06New 90-day high: UK£27.03The company is up 11% from its price of UK£24.39 on 08 October 2020. The British market is also up 11% over the last 90 days, indicating the company’s price trend is similar to the market over that time. Its price trend is also similar to the Chemicals industry, which is up 11% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is UK£25.96 per share.